- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sangamo Therapeutics Inc (SGMO)Assess today's live Sangamo Therapeutics Inc (SGMO) share price, performance and insights using our live NASDAQ: SGMO stock exchange data.
Analyse the historical data and Sangamo Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Sangamo Therapeutics share price buy/sell indicators using real-time data (or discuss the Sangamo Therapeutics (SGMO) stock price today with other investors in the Sangamo Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ SGMO share price (ISIN: US8006771062) to enhance your trading decisions with our free investment tools and resources.
What Is the Sangamo Therapeutics Inc Share Price Today?
The Sangamo Therapeutics share price today is 2.0000.
What Is the Stock Symbol for Sangamo Therapeutics Inc
The stock symbol (or 'ticker') for Sangamo Therapeutics Inc is "SGMO."
What Stock Exchange Does Sangamo Therapeutics Inc Trade On?
Sangamo Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sangamo Therapeutics Inc a Good Stock to Buy?
Determining whether Sangamo Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Sangamo Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Sangamo Therapeutics share price buy/sell indicators using real-time data (or discuss the Sangamo Therapeutics (SGMO) stock price today with other investors in the Sangamo Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ SGMO share price (ISIN: US8006771062) to enhance your trading decisions with our free investment tools and resources.
What Is the Sangamo Therapeutics Inc Share Price Today?
The Sangamo Therapeutics share price today is 2.0000.
What Is the Stock Symbol for Sangamo Therapeutics Inc
The stock symbol (or 'ticker') for Sangamo Therapeutics Inc is "SGMO."
What Stock Exchange Does Sangamo Therapeutics Inc Trade On?
Sangamo Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sangamo Therapeutics Inc a Good Stock to Buy?
Determining whether Sangamo Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
2.0000
-0.0100(-0.50%)
Closed
After Hours
2.0389+0.0389(+1.945%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9300
2.0500
52 wk Range
0.3040
3.1790
SGMO Scorecard
Full Analysis
Quickly burning through cash
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.93002.0500
52 wk Range
0.30403.1790
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
SGMO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
6.2000
Upside
+210.0000%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Sangamo BioScienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Sangamo BioScienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Sangamo BioScienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
Sangamo Therapeutics Inc SWOT Analysis
Genomic Frontiers | Sangamo Therapeutics pioneers innovative genomic therapies, leveraging zinc finger technology and AAV delivery platforms for genetic diseases |
Strategic Alliances | Explore Sangamo's partnerships with Genentech and Pfizer, potentially yielding billions in milestone payments and validating its technological prowess |
Pipeline Progress | Delve into Sangamo's diverse pipeline, including promising developments in Fabry disease treatment and novel approaches to neurodegenerative disorders |
Market Outlook | Analyst price targets range from $2 to $5, reflecting cautious optimism amid financial challenges and the potential of Sangamo's genomic medicine portfolio |
Sangamo Therapeutics Inc Earnings Call Summary for Q4/2024
- Sangamo aligns with FDA on Fabry disease program, potentially accelerating approval by 3 years; plans BLA submission with 1-year data by end of 2024
- $50M milestone payment from Genentech received; hemophilia A program with Pfizer nearing regulatory submission, potential $220M in milestones
- Phase III AFFINE trial for hemophilia A met primary endpoint; Sangamo to earn 14-20% royalties on sales
- First IND for ST-503 (intractable pain) submitted; clinical trials expected mid-2025; company anticipates busy 2025 with potential BLA submissions
- Positive patient feedback on Fabry treatment; potential product launch early 2026; FDA requests data from 32-patient cohort for approval
Last Updated: 13/11/2024, 11:22
Read Full TranscriptCompare SGMO to Peers and Sector
Metrics to compare | SGMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSGMOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.1x | −2.3x | −0.7x | |
PEG Ratio | −0.06 | −0.04 | 0.00 | |
Price/Book | 10.7x | 0.7x | 2.6x | |
Price / LTM Sales | 8.0x | 5.3x | 3.2x | |
Upside (Analyst Target) | 248.3% | 207.0% | 47.0% | |
Fair Value Upside | Unlock | 20.2% | 7.5% | Unlock |
Analysts' Recommendations
4 Buy
4 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.2000
(+210.00% Upside)
People Also Watch
FAQ
What Is the Sangamo Therapeutics (SGMO) Stock Price Today?
The Sangamo Therapeutics stock price today is 2.00
What Stock Exchange Does Sangamo Therapeutics Trade On?
Sangamo Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Sangamo Therapeutics?
The stock symbol for Sangamo Therapeutics is "SGMO."
What Is the Sangamo Therapeutics Market Cap?
As of today, Sangamo Therapeutics market cap is 419.38M.
What is Sangamo Therapeutics Earnings Per Share?
The Sangamo Therapeutics EPS is -0.697.
What Is the Next Sangamo Therapeutics Earnings Date?
Sangamo Therapeutics will release its next earnings report on 19 Feb 2025.
From a Technical Analysis Perspective, Is SGMO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.